Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Stake Raised by GAMMA Investing LLC

GAMMA Investing LLC boosted its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 1,155.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 39,010 shares of the biotechnology company's stock after purchasing an additional 35,902 shares during the period. GAMMA Investing LLC's holdings in Aurinia Pharmaceuticals were worth $314,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Deutsche Bank AG boosted its position in shares of Aurinia Pharmaceuticals by 54.8% during the 4th quarter. Deutsche Bank AG now owns 142,869 shares of the biotechnology company's stock valued at $1,283,000 after purchasing an additional 50,575 shares in the last quarter. Blue Trust Inc. lifted its stake in Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 6,174 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Aurinia Pharmaceuticals by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,314 shares of the biotechnology company's stock valued at $685,000 after purchasing an additional 2,887 shares during the last quarter. Atria Wealth Solutions Inc. acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $135,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $9,662,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 27th.

Aurinia Pharmaceuticals Trading Down 1.9%

Shares of NASDAQ AUPH traded down $0.15 during mid-day trading on Friday, hitting $7.77. 1,199,723 shares of the company traded hands, compared to its average volume of 1,328,417. Aurinia Pharmaceuticals Inc has a 1 year low of $5.20 and a 1 year high of $10.67. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of 27.75 and a beta of 1.15. The company has a quick ratio of 5.26, a current ratio of 5.93 and a debt-to-equity ratio of 0.16. The business has a 50 day moving average of $8.04 and a two-hundred day moving average of $8.20.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its earnings results on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.08 by $0.08. Aurinia Pharmaceuticals had a return on equity of 14.27% and a net margin of 16.11%. The business had revenue of $62.47 million during the quarter, compared to the consensus estimate of $61.06 million. On average, sell-side analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.